Menu

Cédric BORIES

Clapiers

Electionseuropéennes 2024

RETROUVEZ GRATUITEMENTLe résultat des européennes à Montpellier ainsi que le résultat des européennes dans l'Hérault.

En résumé

- PhD in organic chemistry at the University Paul Cézanne (Marseille) in 2005
- R&D director at Azasynth in 2007
- Medicinal chemistry director at Oribase Pharma in 2010
- President at AGV Discovery in 2013

Specialities: Drug Discovery, Medicinal Chemistry, Start-up Creation and Management

Entreprises

  • AGV Discovery - President

    Clapiers 2013 - maintenant AGV Discovery is a pharmaceutical company specialized in rational drug design and early stage drug candidates. Based on a dual model of pharmaceutical development and services, the company makes available to its customers its expertise and skills to propose global solutions which correspond to the expectations of modern medical research, specifically in the area of drug discovery. AGV Discovery services can answer to specific needs but also to more general applications realizing customized services which cover the broad spectrum of needs in drug discovery, and all of this at exceptional prices.

  • Oribase Pharma - Medicinal Chemistry Director

    2010 - 2012 Azasynth and Nova Decision merged in 2010 to give Oribase Pharma, a biotechnologic company specialized in the discovery of kinase inhibitors.

    At Oribase Pharma, I had in charge the chemistry department (Production, customer's projects, intern programs on kinase inhibitors). The chemistry department covers a large panel of activities in medicinal chemistry. Our collaborators were pharmaceutical and academic laboratories.

  • AzaSynth - Scientific Director

    2007 - 2010 After my PhD in 2005, I worked on the creation of Azasynth, a company specialized in organic chemistry. The main activity of Azasynth was to provide several services to pharmaceutical and academic laboratories as custom synthesis or library production.

    At Azasynth, I managed the R&D programs dedicated to the discovery of new interesting building blocks and NCEs as kinases inhibitors. I had also in charge the IP of the company, customer's projects and the management of the Azasynth staff.

    During 3 years, the knowhow of the company was developped and the staff reached 5 people. Programs on NCEs gave very interesting results and conducted to fill our first patents in collaboration with Nova Decision (Montpellier, France).

Formations

Réseau

Annuaire des membres :